Podcasts about GMG

Please visit answersincme.com/ABT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses the clinical evidence for novel complement (C5) inhibitors in the treatment of generalized myasthenia gravis (gMG) and personalized multidisciplinary management strategies. Upon completion of this activity, participants should be better able to: Review the rationale for novel C5 inhibitors in the treatment of generalized myasthenia gravis (gMG); Describe the long-term clinical data of C5 inhibitors for the treatment of gMG; and Discuss strategies to personalize multidisciplinary management plans for patients with gMG.

Please visit answersincme.com/ABT860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses the clinical evidence for novel complement (C5) inhibitors in the treatment of generalized myasthenia gravis (gMG) and personalized multidisciplinary management strategies. Upon completion of this activity, participants should be better able to: Review the rationale for novel C5 inhibitors in the treatment of generalized myasthenia gravis (gMG); Describe the long-term clinical data of C5 inhibitors for the treatment of gMG; and Discuss strategies to personalize multidisciplinary management plans for patients with gMG.

The ASX 200 fell 8 points to 8551 in quiet trade. Banks fell slightly with the Big Bank Basket at $294.91 (0.1%). ANZ the star playing some catch-up up rising 2.2%. Insurers slid, QBE off 0.6% and financial services continued to push higher. PNI up 1.5% and HUB putting on 1.6%. REITs slipped, GMG off 1.3% and SCG down 0.6%. Industrials generally weaker, TCL down 0.6%, BXB off 0.5% and tech under pressure as XRO resumed trade after placement. Off lows but still down 5.3%. The All-Tech Index dropped 1.0%. Retail and travel stocks mixed, LOV down 1.1% with FLT up 0.8%. Pizza and burritos down, KFC up, LNW pushing ahead again, up %. Resources were mixed. Lithium showed signs of life with Vanguard taking a stake in PLS, up 5.6% and MIN rallying 3.6%. The iron ore miners were flat, gold miners fell, NST down 2.3% and EVN off 0.9%. Uranium stocks slightly better, BOE up 2.0% though BMN dropped 9.9% after a cap raise. Oil and gas mixed, WDS off 0.6% with STO up 0.8%.In corporate news, XRO returned to trade, NEU ran hard up 6.1% on US news. AZJ fell 0.3% on an earnings update. Nothing on the economic front. Asian markets mixed, Japan up 1.7%, HK down 0.9%, China down 0.4%. 10-year yields steady at 4.11%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you.If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

The ASX 200 trod water rising 4 points to 8559 as CPI numbers came in below forecast. Narrow trading range. Banks were firm again, CBA up another 1.7% with the Big Bank Basket at $295.09 (+1.5%). Financials also doing well, GQG up 9.1% and XYZ up 1.0% with REITs better on rate cut hopes. GMG up 0.4% and CHC rising 1.2%. Industrials were mixed, retail better on rates, LOV up 1.9% and NCK rallying 3.3%. Travel stocks better too, CTD up 2.2% with LNW soaring as ALL fell 0.9%. SGH continue to push to new highs, QAN up 0.8% with VGN up 3.4% on day two.Resources were once again under pressure. The big three are getting smaller, BHP down 1.0% and FMG off 2.3%. Lithium stocks fell, MIN off 6.0% and PLS falling 3.1%. Gold miners too slipping again as bullion eases back. NST down 2.6% and GMD down 4.0%. Oil and gas stocks continue to suffer despite crude finding buyers, STO down another 1.2% with uranium steady and coal down, WHC off 2.2%.In corporate news, HUM got a NBIO from its chair, DRO soared 19.9% on a new EU contract, PNI down 3.7% as founder sold a parcel, PBH shareholders turned Japanese, SGR got shareholder approval for Bally and Mathieson to take the stakes. XRO in a trading halt with big capital raising and US acquisition worth $4bn.On the economic front, the local monthly CPI came in below forecasts and rate cut hopes emerged. Asian markets better Japan up 0.3%, China up 0.6% and HK up 0.8%. 10-year yields falling to 4.12%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you.If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

The ASX 200 claws back early falls to close down just 8 points to 8524 as CBA hits a new record, up 1.5%. The Big Bank Basket continues higher, sucking in money, WBC up 0.7% and NAB up 0.3% with the Basket up to $284.69 (+1.3). Other financials lacklustre, GQG falling -4.4% on low volumes. REITs better, GMG flat and SCG up 1.1% with industrials mostly weaker, CPU down 1.5%, REA off 0.4% and retail squirming after KMD warning. LOV off 2.8% with PMV down 1.7% and travel stocks also suffering, CTD down 2.3%. Tech stocks eased, WTC off 1.9% despite two new NEDs. The All-Tech Index fell 1.1%. Defensives back in fashion, COL, WOW and WES all better.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

The ASX 200 dropped 7 points to 8541 (0.2%) as nerves crept back in on Iran/Israel issues. Trump flew back to Washington to handle the situation. G-7 now G-6. Banks slipped slightly, CBA down 0.2% and ANZ off 0.5%. The BIg Bank Basket down to $280.41(-0.2%). MQG slid 0.4% with REITs also lower except GMG up 1.1% and other financials mixed too. Industrials pretty much lower across the board, drifting rather than sold off, TCL off 0.8%, REA down 0.5% and TLS falling 0.2%. Retailers mixed, as were travel stocks. Tech wafting around too with the All-Tech Index up 0.2%. In resources, uranium and rare earths stocks back in the spotlight or should it be SPUT light, DYL up 5.7% and LOT up 11.4% with physical buying of spot and short covering still dominating. Gold miners recovered some of the losses yesterday on the Iranian uncertainty as bullion rose, NEM up 2.5% and NST recovered 1.5% after the UBS inspired sell off. Iron ore majors eased back as iron ore fell in Singapore trade again. Oil and gas stocks weakened slightly, STO up 0.5%. In corporate news, it was quiet, too quiet. Asian markets drifted around, Japan up 0.5%. HK off 0.5% and China unchanged.10-year yields steady at  4.25%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

The ASX 200 started strong but as news of the Israeli attack came through, we turned negative. The index fell 18 points to 8547 (0.2%) for a gain of only 31 points this shortened week. Performing much better than the US which had futures off between 1.5-1.8%. Stand-out sectors were not unexpectedly gold miners and oil and gas stocks. Crude and bullion jumping on the Iranian news. NST up 5.1% and EVN rising 5.5% with BGL up 4.3%. Resources generally were flat, BHP down 2.6% with FMG slightly firmer. MIN took a breather and PLS rose 0.4%. LYC rallied 3.8% on rare earth promise, WDS showed a clean pair of heels up 7.4% with STO up 3.7% and KAR the real star up 10.9%. Uranium stocks fell on attack news. Industrials slid, banks off slightly, CBA down 0.7% with the Big Bank Basket down to $281.21 (-0.5%). Other financials slipped, GQG down 1.4% and XYZ down 2.4%. Insurers gained a little, REITs fell, GMG bucked the trend up 0.2%. Tech stocks fell in sympathy with Nasdaq futures. XRO down 0.4% and WTC falling 2,4% with the index down 1.7%. Retail stocks dropped 24.7% on AX1 earnings warning, JBH fell 1.8% and travel stocks down, QAN off 4.9%. In corporate news, Brookfield sold a large parcel of its DBI holding, the stock falling 6.2%. Nothing on the economic front. Asian markets down on war worries. Japan down 0.9%, HK off 0.7% and China down 0.6%.10-year yields falling to 4.16%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Please visit answersincme.com/BFK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses strategies to optimally incorporate FcRn antagonists into care plans for patients with generalized myasthenia gravis (gMG). Upon completion of this activity, participants should be better able to: Describe the disease burden of generalized myasthenia gravis (gMG); Review the evidence for the use of neonatal fragment crystallizable receptor (FcRn) antagonists in gMG; and Outline strategies to optimally incorporate FcRn antagonists into the care of patients with gMG.

Please visit answersincme.com/BFK860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in neurology discusses strategies to optimally incorporate FcRn antagonists into care plans for patients with generalized myasthenia gravis (gMG). Upon completion of this activity, participants should be better able to: Describe the disease burden of generalized myasthenia gravis (gMG); Review the evidence for the use of neonatal fragment crystallizable receptor (FcRn) antagonists in gMG; and Outline strategies to optimally incorporate FcRn antagonists into the care of patients with gMG.

In this KE Report company update, we catch up with Craig Nicol, Founder and CEO of Graphene Manufacturing Group (TSX.V:GMG - OTCQX:GMGMF), to dive into the company's latest developments across all divisions - graphene production, G® Lubricant, batteries, and THERMAL-XR®.   Key topics include: Second Generation Graphene Plant: Early works are underway on a next-gen production facility that will boost graphene output 20x - up to 10 tonnes annually using the same inputs. This modular, scalable design could enable global rollout, with full commissioning targeted by mid-2026. Cost Efficiency and Environmental Advantage: The Gen 2 process is expected to significantly lower graphene production costs - potentially below the cost of mining graphite. G® Lubricant Commercialization: New independent engine tests show a 10% fuel saving and 33% drop in emissions. Sales have launched globally via g-lubricant.com, with distributor discussions underway. U.S. sales are pending EPA approval. Battery Division Progress: GMG is working with a top-tier U.S. battery innovation center to streamline pouch cell development. Craig outlines a timeline for customer testing and commercial readiness. THERMAL-XR® + Strategic Partners: While EPA approval is still needed for the U.S., interest remains strong - particularly from data centers and industrial HVAC users. New packaging and website updates are helping broaden access. OEM partnerships and licensing discussions are also discussed. For follow-up questions, email fleck@kereport.com. Stay tuned for another GMG update in about a month!   Click here to visit the GMG website to learn more about the Company.

The ASX 200 gave up strong early gains closing down 27 at 8565 (0.3%). US futures and lack of detail weighing on sentiment as Asian markets generally weaker. Banks slid slightly, CBA down 0.5% with NAB down 0.2% and the Big Bank Basket down to $262.66 (-0.5%). MQG whacked 1.6% with insurers also under pressure. REITs mixed, GMG off 1.2%. Industrials generally lower, ALL off 1.6% with retail down, led by SUL off 1.6% and BAP falling 2.7%. Travel stocks also under pressure, CTD down 3.1% and WEB off 2.8%. Fast food falling, DMP down 4.9%. REA fell 1.1% and TWE down 1.3% with TLS up 1.0% as defensives back in focus. In resources, gold miners back in demand, GMD up 6.0% and NEM up 3.0%. The Three Iron Ore amigos all down, BHP off 1.8% with FMG off 3.4%. Lithium stocks back under pressure, MIN off 7.6% and PLS falling 6.0%. Rare earth giant LYC rose 0.8%. Oil and gas stocks gave up strong early gains as the crude price fell back, KAR up 2.0% and BPT bouncing 2.4%. Uranium ok, nothing spectacular, DYL up 1.1% and PDN up 0.8%. In corporate news, CTT fell 31.2% on a trading update and a large line of stock going through. MVF rose 9.1% as its CEO resigned. COH up 0.7% after downgrading its earnings outlook. Nothing on the economic front today. Asian markets weaker, Japan off 0.6% and HK off 0.9. China unchanged.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

ASX 200 jumps to a record high before seeing profit taking creep in and close up only 5 to 8592 (0.1%). News from the UK on the trade talks were lacking in detail, US futures weaker before the CPI number tonight. Banks eased back with CBA off 0.3% and the Big Bank Basket down to $284.04 (0.2%). MQG fell 0.6% with insurers slightly weaker. REITs were firm, GMG up 0.2% and VCX up 2.4%. Industrials mixed, WES fell 0.6% with QAN falling 1.3% in news it was closing Jetstar Asia. Tech steady with REA up 0.6% and XRO falling 2.3%.  Resources were interesting again, BHP rallied 1.5% with FMG up 3.5%, gold miners fell again despite bullion rising, lithium stocks squeezed higher, PLS upgraded its MRE, up 5.6% and MIN rallying again up 3.2%. Uranium stocks fell, PDN was off 2.7% and LOT was down 8.6%. WDS and STO better, with BPT down 7.5% on a broker downgrade. In corporate news, ZIP raced 15.5% ahead on another guidance upgrade, JLG revealed a NBIO with no price tag attached. MVF bounced after the drubbing yesterday and FBU rose 10.0% on M&A talk. Nothing on the economic front. Asian markets better on trade talk, Japan up 0.4%, HK up 1.1% and China up 0.9%.10-year yields steady at 4.29%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

ASX 200 kicks off the week in style, up 72 points to 8587, a new record. Banks kicked again with CBA up 1.2% and NAB running 1.5% higher. The Big Bank Basket up to $284.50 (1.2%). MQG kicked 1.1% with financials generally doing well, IFL up 0.9% and ZIP up 6.4% on BNPL reforms. REITs also in demand, GMG up 2.1% and MGR better by 2.2% with healthcare better too, CSL up 0.9%. Retail stocks rallied as JBH gained 2.1% and ALL up 3.6% and tech stocks in demand, WTC up 2.4% and XRO rising 1.8% with the all-tech index up 1.6%. In resources, iron ore miners mixed, gold miners sold down aggressively, GMD off 1.3% with EVN down 3.8% and shorts in the lithium space gaining momentum. PLS up 5.5% and LTR up 4.8% with MIN gaining 5.1%. Rare earth stocks remain in favour and oil and gas stocks better. Uranium stocks tried to put in another stellar day but off the highs, PDN up 3.6% and BOE up 2.1%. In corporate news, ASB rallied another 7.3% as the US approved Hanwha holding. NXT up 5.2% on Malaysian expansion plans. MVF cratered 26.9% on another clinical issue. JLG in a trading halt pending a change of control announcement. Nothing on the economic front, Asian markets slightly higher, Japan up 0.2% and HK down 0.5% and China down 0.6%. 10-year yields at 4.26%, steady. Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

The ASX 200 tried hard to attack and sustain the all-time high but failed, dropping 3 points to 8539 (0.1%). Banks were flat as some profit taking crept in, CBA up 0.1% with the Big Bank Basket up to $282.74 (0.1%) insurers down slightly, QBE off 1.4% and financials finding sellers here. REITs mixed, GMG up 1.1% with GPT also firming. Industrials generally lower, CPU fell 1.2% with retailers giving back some of the gains, JBH down 2.0% and CTD off 1.1%. Tech better, the index up % with TNE and XRO making modest gains. In resources, the iron ore miners rose slightly, FMG the best up 1.5%, but the real action was in critical metals either rare earths, or lithium. LYC jumped 12.5% and ILU up 7.1% with MIN rallying 14.8%. PLS too doing well, up 12.5% as shorts moved to cover on Chinese reluctance to make a deal and rare earth exports not forthcoming. IPX soared 28.8% on a DoD deal for US$99m. Gold miners fell, GMD down 2.5% with EVN off 1.6% and CYL falling 3.5%. Uranium stocks flat, coal firmed, WHC up 1.8%. In corporate news, TYR fell 10.4% on news its CEO was leaving. CAT dropped 1.0% on an acquisition and PAC fell 5.0% on a media report on overvaluations. In economic news, Household spending rose 0.1% in April, the seasonally adjusted balance on goods decreased $1,479m in April. Asian market mixed, Japan down 0.4% and HK up 0.6% China flat. 10-year yields lower at 4.24%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

ASX 200 finished up 75 points at 8542 (0.9%) close but no cigar. CBA became the first $300bn market cap stock on the ASX. Not surprisingly a new record, the Big Bank Basket up another 1.3% to $282.44. WBC the best of the bunch, up 1.5% with MQG up 1.5% and GQG lifting 4.3%. REITs also firmed GMG up 0.7% on data centre demand. Retail stocks also in demand following lacklustre GDP numbers and hopes fro more rate cuts. LOV romped 9.1% higher as Mark McInnes joined as deputy chair. JBH up 2.1% and HVN up 3.0% with travel and fast-food stocks rallying too. Defensives sold down as WOL, COL and TLS fell slightly, tech gained a little, WTC up 1.1% and TNE up 1.4% with the All-Tech Index up 0.9%. In resources BHP up 1.0% with FMG rising 1.6% as iron ore found some strength in Singapore. Gold miners sold down, EVN down 2.7% with GMD off 2.8% and SPR losing 0.9%. Uranium stocks spurted higher on Meta moves in US to shore up nuclear power deals, Lithium also saw buyers return, PLS up 5.7% and LTR rising 6.1% with MIN doing well, up 9.2%. Oil and gas better with CRN sorting some liquidity issues out, up 38.1%. In corporate news, MYX was issued with the scheme termination notice falling 5.3%, IEL fell another 2.6% after the 48% loss yesterday, and PBH had an upgraded bid of 120c. On the economic front, GDP came in below expectation at 0.2%. Asian markets firmed, Japan up 0.8%, HK up 0.6% and China up 0.5% 10-year yields steady at 4.25%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Guest: John A. Morren, MD, FAAN, FAANEM The symptom variability, prolonged asymptomatic periods, and inconsistent presentations of generalized myasthenia gravis (gMG) often lead to significant diagnostic delays and misdiagnoses. Based on recent studies, these delays then correlate with increased disease severity, longer time to symptom control, and worsened quality of life. Here to help uncover the hidden toll of diagnostic delays on patients with gMG is Dr. John Morren. He's the Program Director of the Neuromuscular Medicine Fellowship at Cleveland Clinic and an Associate Professor of Neurology at Cleveland Clinic Lerner College of Medicine of Case Western Reserve University.

ASX 200 up 53 points to 8647 (0.6%). A solid rally driven by bullion and banks. The Big Bank Basket rallied to $278.81 (+1.2%). CBA up another 1.3%, with ANZ doing well up 1.3%. MQG rose 0.9% and IFL up 2.7% on a broker upgrade, Insurers better, SUN was out and up 2.4% with IAG doing well, rising 2.9%. REITs rallied too, GMG up 1.1% and CHC rising 3.1%.  Industrials in demand across the board, JBH up 1.9% with WOW and COL better, TLS continuing to push ahead up 1.0% with QAN up another 2.0%. Healthcare mixed, SIG up 2.3% and CSL off 1.0%. Tech stocks rose, with the All-Tech Index up 0.3%. In resources, iron ore stocks drifted lower as iron ore fell on Chinese PMI. Gold miners off highs, but still strong, NEM up 4.3% with GMD gaining 4.6% and OBM up 5.9%. Lithium stocks falling again, PLS down 0.4% and MIN hit 5.5%. Oil and gas stocks rose with crude, uranium still under pressure again. DYL down 1.9% and PDN off 1.3%.  In corporate news, IEL fell 48.1% on a massive downgrade and nasty outlook statement, TEA ran 8.6% on a special dividend, DMP fell 2.2% after a raft of executive changes. In economic news, the RBA minutes helped sentiment, Chinese PMI dropped to 48.3. Asian markets slightly higher, Japan up 0.1%, HK up 1.1% and China up 0.5%. 10-year yields steady at 4.26%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

歡迎嚟到 搞乜咁科學 GMG Science 第36集！今集嘅主題係《浴簾貼大腿與望落似貓女Shower Curtain Sticks & Female Cat Trick

The ASX 200 had a late surge to finish the month with a gain today of 25 points to 8435. ASX records best month since January. Up 3.8%. Banks yet again showed the strength as CBA rose 0.9% with the Big Bank Basket up to $275.55 (1.1%). WBC surged 2.7% and NAB up 1.3% with some month end window dressing. Insurers slid slightly, QBE down 1.3% with REITS up. GMG up 1.3% and VCX rising 1.2%. Industrials found a footing, BXB up 1.0%, WOW and COL firmed, and ORG up 2.1%. Tech slipped slightly with WTC down 1.5% and XRO off 0.8%. Healthcare mixed, In resources, mixed in the majors, BHP up 0.3% and FMG down 1.9%. Gold miners were better, NST up 3.2% with GMD up 4.4%, VAU up 3.5% as some window dressing helped. Lithium stocks slid on a broker downgrade to carbonate prices, PLS down 5.7% and IGO off 5.4%. WDS fell 2.1% and STO off 0.9%. Uranium stock eased back, coal miners fell, WHC off 1.8%. In corporate news, HCW leapt on rent relief for Healthscope, NWH up on a RIO contract and FND down nearly 9% on results. In economic news, retail sales slipped. Asian markets fell with Japan down 0.9%, China down 0.3%, and HK down 1.5%. 10-year yields at 4.28%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

The ASX 200 limped to a 13-point rise at 8410 (0.2%) missing out on the US fun as the tariffs got knocked back and Nvidia ran on results. Banks were slightly better with NAB and WBC doing ok, CBA unchanged and the Big Bank Basket up to $272.57 (+0.4%). Financials were strong, MQG up 1.7% and XYZ rising 3.0%. REITs fell, GMG down 1.4% and SCG off 1.1%. Industrials firmed, TCL up 0.4%, WES up 0.2% and TLS pushing ahead up 0.8%. Tech was better but not stunning, WTC up 1.2% and the All-Tech Index up 0.6%. Retail better, TPW up 1.9% and BRG rising 0.4%. Resources were weighed down by BHP and RIO, the ugly sisters, LYC fell 2.1% and S32 off 1.0%. Gold miners were mixed, NST down 0.7% and EVN up 0.8% after a rocky start. Bullion fell on trade news, GMD rose 0.9% as broker upgrades came through. WDS kicked 2.8% on broker optimism on NW shelf deal and oil prices kicking up. Uranium back in the doghouse with DYL off 3.2% and PDN down 5.0%. In corporate news, CIA up 0.5% on record results, RSG fell another 2.4% despite seeking further information from Guinea government. ELD up 1.1% as the ACCC voiced concerns on its acquisition of Delta. Nothing on the economic front, Asian market rallied on the US news. 10-year yields steady at 4.37%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

The ASX 200 limped along to close down 11 points at 8397 as a Japanese bond auction underwhelmed, and CPI came in a little hotter than expected. Blame eggs. Banks went a little squishy, with CBA falling 0.9% and the Big Bank Basket down to $271.48 (-0.9%). Insurers also fell with QBE off 1.6%. Other financials were mixed, XYZ rose 4.9% on better US consumer sentiment and bitcoin. REITs are better today, GMG is up 0.9%, and SCG is rising, Industrials started well but fizzled, WES is down 0.1%, and retail is falling slightly. Tech was better following US tech, and the All-Tech Index was up 1.3% with WTC up 0.4%. REA bounced 1.9% after its fall yesterday on ACCC News, and TLS slid 0.2% on some broker downgrades. Resources are under a little pressure, RIO off 0.9% and lithium stocks down, MIN downgraded guidance again, down 5.5% with gold miners a little mixed, NST off 0.8% and RMS up 1.1%. MAC rose 20.4% as it got the Harmony bid, uranium was a little mixed, BOE was off %, and LOT was up 5.1%. WDS jumped 3.2% on NW Shelf news, and finally, STO is up 1.9%. Coal stocks also rallied, WHC up 2.7%. In corporate news, WEB jumped 12.4% on much better than expected results, ALQ fell 7.6% after completing its capital raise, IFT disappointed, and FPH fell 4.8% despite a 43% jump in revenues. On the economic front, CPI was unchanged at 2.4%, the RBNZ cut rates again by 25bps. 10-year yields rose to 4.33%. Asian markets, as usual, mixed, Japan up 0.3%, China up 0.1% and HK down 0.8%Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

The ASX 200 finished up 47 points to 8408 (0.6%) ahead of US and UK reopening tonight. The banks led the market higher after a lacklustre session earlier, CBA up 0.8% and ANZ rising 1.4% with the Big Bank Basket up to $273.93 (+1.0%). MQG kicked 1.4% with other financials doing well too, NWL up 1.4% and CGF up 1.1%. REITs are flat, GMG is down 0.5%, with industrials doing better, and BXB is up 3.0% with ALL up 1.9%. TLS rallied another 0.4% on its investor day comments; Retail also improved, JBH was up 1.0%, and LOV was up 4.2%. Tech is better, WTC is continuing to push ahead after its large acquisition, XRO is up 1.5%, and the All-Tech Index is up 0.5%. In resources, iron ore stocks cheered up, BHP up 0.2% and RIO unchanged after earlier bigger falls.  Gold miners eased back, EVN down 3.1% with VAU off 2.2% and GMD down 0.2%. LYC fell 2.5% with PLS off again. Uranium stocks took a break, shorts licking their wounds, Oil and gas flat, coal slightly better. In corporate news, REA fell 3.5% on ACCC inquiry, VUL down 0.5% as it commenced drilling. On the economic front, Chinese Industrial profits climbed 3% last month from a year earlier, beating forecasts of 2.6%. Asian markets mixed again, with Japan up 0.4%, China down 0.5%, and HK up 0.3%. 10-year yields falling to 4.31%. Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

The ASX 200 limped 12 points higher to 8361 (+0.2%) ahead of a long weekend in the US. For the week, we are up 17 points. Banks once again firm, CBA up another 0.7% with the Big Bank Basket up to $271.95 (+0.6%). ANZ outperforming. Insurers rose slightly, and financial services better, with XYZ up 5.5% and GQG bouncing 2.4%. REITs were firm, GMG up 2.2% and SGP rising 0.2% as 10-year yields steadied to 4.45%. Healthcare is flat, tech stocks are slightly better, XRO is up 0.7%, and the Index is up 0.9%. ‘Old Skool' platforms are doing ok, REA up 0.5% and CAR up 1.3%. TLS continues to push ahead. Retail better, JBH up 1.6% and MYR up 5.4% following a sales update. Utilities are under a little pressure on an ORG downgrade, off 1.1%. Resources were mainly weaker; iron ore stocks eased back, FMG was down 2.4%, with gold miners drifting slightly lower. Uranium stocks are on fire as Reuters reported that Trump will sign an order to benefit the uranium and nuclear industry. BOE up 12.1%, PDN up 6.7% and SLX up a huge 15.3%. Oil and gas are moving a smidge higher.In corporate news, BEN results out this morning, up 0.8%, and NUF continued to fall as one broker lost faith in the stock. Nothing locally on the economic front, Japanese CPI picked up more than anticipated, 3.5% excluding fresh food. Asian markets firmed, Japan up 0.6%, and HK up 0.3%. Dow futures flat, Nasdaq futures down 0.3%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

ASX 200 followed US futures down on Moody's downgrade, off 49 points at 8295 (0.6%).  Banks tried to hold off the selling, but the Big Bank Basket rose to $267.97 (+0.3%). MQG fell 3.4% as it went Ex-dividend. Financials slid, ZIP off 6.2% and PPT down 2.9% with PNI off 2.4%. Insurers unchanged, REITs fell as bond yields pushed up a little to 4.51%. GMG down 0.6% and SCG off 0.3%. Industrials eased back too, CPU down 1.0% and WTC falling 2.1% with retail and travel stocks down. DMP fell 2.6% as CEO ANZ resigned. Resources pounded by lower commodity prices, BHP off 2.4%, RIO down 1.3% and FMG being crunched 4.9%. Lithium stocks depressed, PLS off 10.0% as the shorts came roaring back in LTR too off 16.6%. MIN fell 8.8% after announcing a new chair. Gold miners were better on haven buying, NST up 1.9% and NEM bouncing 2.5%. Coal stocks hit hard as NHC downgraded guidance, off 7.1% with WHC down 3.4%. Uranium stocks also seeing fallout, PDN down 4.1% and the oil and gas sector easing back too. In corporate news, MYX in a trading halt pending more information on the Cosette bid, EOS jumped 14.7% on a Euro contract, LLC down 0.4% after signing JV with the King. On the economic front, Chinese data mixed. Asian markets eased back in line with US futures.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

The ASX 200 wilted slightly from 8400, to close up only 46 points at 8344, touching a 3-month high. Today, it was all about resources as BHP, RIO, and FMG rallied. The gold sector, too, was back in demand, with GMD up 4.4% and NEM rising 3.6% after a bruising week. LYC bounced too much 2.7% with LTR continuing to find friends and shorts covering. Up another 3.2%. In oil and gas, WDS unchanged and STO rose 0.5%, with uranium stocks giving back some recent gains, PDN down 8.0%, and BOE off 7.2%. Banks took a breather with NAB pushing higher again, CBA off slightly, and MQG fell 1.5% with IAG down 2.8%. The Big Bank Basket $267.18 (+0.1%) Financials were stronger, PNI up 2.8% and IFL rising 1.2%.  ZIP is up another 2.4%. REITs also benefitted from lower yields and pushed higher, GMG up 2.9% and SCG rising 2.5%.  Healthcare was better as CSL rose 1.4% with industrials a slight green tinge. TCL is up 0.9%, and QAN is doing well, Retail is, too, ahead of RBA next week. Tech slipped, XRO was down 1.1%, and WTC was off 2.2%. The All-Tech Index is down 0.1%. In corporate news, APX jumped 18.7% on an update at the AGM, NWH shrugged off Valhalla news, and DXS went down 1.1% after APAC moved on breach of contracts.  Nothing locally on the economic front, Japanese GDP fell slightly, and China and HK went down 0.6%. 10-year yields down to 4.45%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

The ASX 200 rose 18 points to 8298 (+0.2%) as the banks put in another solid day. CBA is up 1.3% with NAB once again slightly outperforming, ANZ up 1.7% with the Big Bank Basket up to $266.85 (+1.3%). MQG rallied 1.2% with other financials mixed. Insurers better, IAG rose 5.7% after signing a deal with RACWA. Up 5.7%. REITs were once again under pressure as yields continued higher as job numbers came in better than expected. SCG down 1.9% and GMG off 1.0%. Industrials rose, WES up 2.2%, and ALL recovered some of the dips yesterday,y up 1.9%, with WOW and COL slightly better. Tech rallied, and XRO released some good numbers, rising 4.7%. Resources failed to launch again, BHP down 0.7% with RIO off 0.4% and gold miners under siege as bullion falls again. GMD down 3.2% and NEM off 4.0%. Base metal and lithium stocks eased, MIN up 1.9%. Oil and gas slid back, WDS down 1.8%, and uranium mixed again.In corporate news, GNC leaped 8.8% on a positive update, and NWH fell 8.3% after a warning on the Valhalla steelworks sale process. MYX jumped 8.2% after Deloitte reviewed the Cosette $672m deal. TWE fell 5.2% as the CEO stepped down.On the economic front, the labour market showed strength, with a jump of 89k jobs in April, more than the 20k forecast. Asian markets drifted lower, with Japan down 0.9%, HK down 1.0%, and China down 0.7%. Dow futures down 0.5%, NASDAQ futures down 0.2%. Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

歡迎嚟到 搞乜咁科學 GMG Science 第35集！今集嘅主題係《古法黃龍湯與計數搵人幫 Valuable Poop & Indispensable Group

ASX 200 kicks higher, just up 2 points to 8234 (+0.0%) after losing momentum as the day wore on. US futures are up strongly on hoped-for details on US/China trade negotiations. Dow futures up 1.1%, Nasdaq futures up 2.1%. Gold fell, miners under pressure with GMD down 5.7% and EVN off 3.7%. Base metals and lithium stocks are better, MIN up 8.3% and LTR roaring ahead, up 12.6%. S32 is also having a good day on CEO retirement. The stars were for iron ore stocks on China hopes, BHP up 2.3% and RIO up 2.1%, with FMG only managing half that rise. Oil and gas stocks were also better, with WDS up 2.0% and KAR up 5.1%. Uranium stocks also firmed again. Banks were flat as NAB went Ex-dividend. Down 2.3% and the other three mixed. The Big Bank Basket is down to $263.16 (-0.2%). MQG rose 2.1% as its run continued, GQG had a great day up 8.0%, and REITs were a little underwhelming. GMG rose 1.6% on a broker upgrade. Industrials mixed, WOW fell 1.5% after announcing price cuts. Drug companies fell on news that Trump was going to cut drug prices in the US.In corporate news, DNL rose 2.0% as it sold the fertiliser distribution business to RIC. Nothing on the economic front. Asian markets were firm again. Japan up 0.3%, HK up 1.4%. 10-year yields rose to 4.37%.Want to invest with Marcus Today? The Managed Strategy Portfolio is designed for investors seeking exposure to our strategy while we do the hard work for you. If you're looking for personal financial advice, our friends at Clime Investment Management can help. Their team of licensed advisers operates across most states, offering tailored financial planning services.  Why not sign up for a free trial? Gain access to expert insights, research, and analysis to become a better investor.

Della Schmidt: President and Chief Executive Officer for Greater Mankato Growth! Join us for an in-depth conversation with a community champion who has built a legacy supporting regional growth. With an impressive record in Southern Minnesota, Della has such a wealth of knowledge for navigating difficult interpersonal dynamics, leading by example, and kickstarting local economies. Her humor and wit during this conversation reminded us just how lucky Mankato is to have her at the helm of GMG. Thank you, Della, for sharing your story with us!

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for April 21-April 27, 2025: FDA Approves Pz-cel (Zevaskyn) Gene Therapy for RDEB The FDA has approved pz-cel, the first autologous gene therapy for RDEB, following pivotal Phase 3 data demonstrating efficacy and safety in wound healing. FDA Approves Upadacitinib, Expanding Treatment for Adults With Giant Cell Arteritis Upadacitinib has been approved for giant cell arteritis, supported by Phase 3 data showing its potential to induce sustained remission and reduce corticosteroid reliance. FDA Approves Nipocalimab Generalized Myasthenia Gravis for Adults, Children Nipocalimab received FDA approval for gMG in antibody-positive patients aged ≥12, expanding therapeutic options across major serotypes. Semaglutide Improves Steatohepatitis, Fibrosis in Phase 3 MASH Trial Phase 3 trial results show semaglutide significantly improves steatohepatitis and fibrosis markers in patients with MASH, without worsening liver histology. Increased Fasting Blood Glucose Triples Risk of Heart Damage in Adolescents International data links elevated fasting glucose and insulin resistance in adolescence to markedly increased future risk of heart damage, especially among females.

Rinvoq approved for giant cell arteritis; telehealth companies collaborate with Novo Nordisk for Wegovy access; epidermolysis bullosa wound healing treatment approved; Imaavy approved for gMG; New nasal powder approved for migraine treatment.

CME credits: 0.75 Valid until: 30-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/treatment-advances-in-generalized-myasthenia-gravis-a-pathophysiology-driven-framework-leveraging-fcrn-therapeutics/29537/ Traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial for many patients in the short term but often come with unacceptable side effects. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) has created a groundbreaking paradigm shift in our approach to both the short- and longer-term management of affected patients. Join Drs. Vera Bril and Neelam Goyal as they take a deep dive into this topic and discuss how FcRn inhibitors are changing the therapeutic landscape of gMG.=

Nicholas J. Silvestri, MD, FAAN - From Established to Emerging Therapies: Expert Perspectives on the Latest Evidence Base on FcRn Inhibitors for gMG

This week Ronnie and Marc have risen from the dead where the full GMG crew are finally together to discuss life after podcasting, being a dad, Mines of Moria, worship ministry, Nintendo Switch 2, Lost TV Show on Netflix, Easter, Wrestlemania, and so much more! – http://linktree.com/thegmgpod – All of our links can be found on the LinkTree link including our audio podcast (Apple, Spotify, etc.), YouTube, Twitch streaming channels, Discord, Patreon, GMG Merchandise, Twitter, Facebook, Instagram, and E-Mail. – Listen as Lucas, Patrick, and Ryan talk about video games, TV, movies, sports, Jesus, but most importantly, life...the greatest and most difficult game of all. And you shouldn't go at it alone, so we are gonna do it with you on this fine morning.

歡迎嚟到 搞乜咁科學 GMG Science 第34集！今集嘅主題係《無可能都會發生與用念力瘦身 Improbable Hits & Mindfulness to Stay Fit

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/autoantibodies-explained-anti-achr-anti-musk-and-their-diagnostic-role/32728/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/diagnostic-advances-in-gmg-effective-tools-and-techniques/32727/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 0.75 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/treatment-advances-in-generalized-myasthenia-gravis-clinical-and-laboratory-criteria-for-diagnosis-and-optimal-treatment-selection/29533/ The adult and pediatric diagnostic and treatment landscapes of generalized myasthenia gravis (gMG) are both similar and different. While current traditional therapies are often effective in the short term, selecting the most appropriate short- and longer-term treatment for each patient, whether adult or pediatric, brings with it unique individual challenges. These challenges include how best to utilize newer targeted agents in the treatment of gMG, such as the neonatal Fc receptor (FcRn) inhibitors. Join Drs. Vera Bril and Jonathan Strober as they tackle these issues from both the adult and pediatric perspective.=

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/living-with-gmg-navigating-personal-professional-and-mental-health-challenges/32726/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/traditional-mg-treatments-balancing-benefits-risks-and-side-effect-management/32729/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/precision-medicine-for-gmg-tailoring-treatments-based-on-patient-profiles/32735/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/preventing-myasthenic-crisis-early-signs-and-critical-interventions/32734/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/ocular-to-generalized-mg-how-and-why-the-disease-evolves/32733/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/managing-side-effects-in-fcrn-therapy-best-practices-for-gmg/32732/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/new-frontiers-in-mg-how-fcrn-antagonists-are-changing-mg-therapy/32731/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

CME credits: 1.00 Valid until: 02-04-2026 Claim your CME credit at https://reachmd.com/programs/cme/a-scientific-look-at-fcrn-antagonists-mechanisms-of-action-explained/32730/ While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.

  Craig Nicol, Founder and CEO of Graphene Manufacturing Group (TSX.V:GMG - OTCQX:GMGMF) joins me to answer listener questions and provide insights into the company's growth strategy, revenue potential, and commercialization efforts of the G® Lubricant and THERMAL-XR.   GMG recently announced a $5 million bought deal financing, and Craig explains how these funds will be allocated to expand production, grow sales teams, and pursue an uplisting to a major U.S. exchange. While production capacity can scale significantly, the company is prioritizing sales and market penetration before making major capacity expansions.   A key focus is on G Lubricants and Thermal XR, two of the company's three divisions. Craig shares details on current sales efforts, distributor partnerships, and ongoing trials with major corporations, including a successful energy savings case study with a Singapore bank in collaboration with Cushman & Wakefield.    GMG is also exploring multiple revenue channels, including direct-to-consumer sales, distributor partnerships, and collaborations with OEMs and large industrial players. Craig discusses how G® Lubricant is gaining traction in the trucking industry, where fuel efficiency improvements could drive significant demand. He also provides updates on EPA approvals, new product launches for individual usage, and how GMG is positioning itself as a leader in graphene-enhanced solutions.   Looking ahead, GMG is balancing commercial sales growth with R&D advancements, ensuring the company can rapidly scale production and maintain high profit margins. Craig outlines the expected revenue drivers for 2025 and beyond, how the company is working with major corporations in a wide range of industries, and when investors can expect to see meaningful revenue impact.   Please keep the questions coming! Email me at Fleck@kereport.com.   Click here to visit the GMG website to learn more about the Company.

歡迎嚟到 搞乜咁科學 GMG Science 第33集！今集嘅主題係《一個人生B與叻過ChatGPT Baby Making DIY & Human Outsmarting AI》

The hilarious Bob Levy (host of Out Of The Coffin) returns to the podcast for the first of the St Patrick's Day themed episodes. Bob talks about the Anthony Cumia vs Kevin Brennan feud, how Opie might ruin Cumia's new radio job, Bob reacts to live streamers crashing their car on the air, Bob also talks about the comedic potential of the upcoming Steel Toe Morning Show court trial.Joining us on this episode are returning co-hosts Quadfather & Ekul Pineapple. Don't play this episode around kids. FOLLOW THE GUESTS===================Bob Levy https://x.com/levy_sirEkul Pineapple https://x.com/EkulPineappleQuadfather https://x.com/QuadfatherDBecome a supporter of this podcast: https://www.spreaker.com/podcast/it-s-hughezy-hello--3476000/support.

19 Feb 2025. We had two sets of record numbers from Dubai: DIFC and private jet movements. Economist Daniel Richards shared the economic significance. Plus, as millionaires and billionaires converge on the Dubai International Boat Show, we speak to the boss of UAE boat builder Gulf Craft. And, the boss of GMG on how they’re transforming food retail and supporting UAE’s food security. See omnystudio.com/listener for privacy information.